CLLS Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

3.100

Open

3.100

VWAP

3.09

Vol

13.48K

Mkt Cap

309.88M

Low

3.070

Amount

41.66K

EV/EBITDA(TTM)

--

Total Shares

100.61M

EV

172.89M

EV/OCF(TTM)

--

P/S(TTM)

3.98

Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development, and commercialization of rational genome engineering technologies. The Company develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction, and biotherapeutics fields. Cellectis SA operates several subsidiaries. The Company operates in France and the United States, among others.

Show More

Events Timeline

(ET)

2026-05-11

16:40:00

Cellectis Reports $188 Million in Cash, Sufficient to Fund Operations into Q4 2027

2026-05-11

16:40:00

Cellectis Q1 Revenue at $7.5M, Below Consensus

2026-04-13 (ET)

2026-04-13

16:50:00

Cellectis and Allogene's cema-cel Shows Positive Clinical Data

2025-12-15 (ET)

2025-12-15

17:50:00

Allogene Therapeutics Wins Arbitration Against Cellectis

2025-12-15

17:00:00

Cellectis Announces Arbitration Decision Against Servier

2025-11-07 (ET)

2025-11-07

16:32:54

Cellectis announces Q3 adjusted EPS of 2 cents compared to a loss of 22 cents in the previous year.

News

Newsfilter

06-11Newsfilter

Cellectis Presents Final Phase 1 Data from BALLI-01 Trial

seekingalpha

06-10seekingalpha

Cellectis CAR-T Therapy Receives FDA RMAT Designation

stocktwits

06-09stocktwits

Cellectis Receives FDA RMAT Designation, Stock Soars

Newsfilter

06-09Newsfilter

Cellectis Receives FDA RMAT Designation for CAR-T Therapy

Newsfilter

05-20Newsfilter

Cellectis to Hold Annual General Meeting on June 25, 2026

Newsfilter

05-11Newsfilter

Cellectis Reports Q1 2026 Financial Results and Business Update

4 Analyst Rating

Wall Street analysts forecast CLLS stock price to rise

2 Buy

2 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

4.00

Averages

7.00

High

9.00

Current: 0.000

Low

4.00

Averages

7.00

High

9.00

Barclays

Overweight

initiated

$9

AI Analysis

2026-05-28

Reason

Barclays

Price Target

$9

AI Analysis

2026-05-28

initiated

Overweight

Reason

Barclays initiated coverage of Cellectis with an Overweight rating and $9 price target. The company is focused on the development of allogenic CAR-T therapeutics for various cancers, the analyst tells investors in a research note. The firm says Cellectis' allogenic platform allows for potentially quicker reaction time from diagnosis to treatment than autologous CAR-T therapies, opening up treatment settings that were previously inaccessible.

Clear Street

Bill Maughan

initiated

$9

2025-12-22

Reason

Clear Street

Bill Maughan

Price Target

$9

2025-12-22

initiated

Reason

Clear Street analyst Bill Maughan initiated coverage of Cellectis with a Buy rating and $9 price target. Cellectis has produced "strong" efficacy data from its initial program, lasme-cel in acute lymphoblastic leukemia, and "an encouraging initial efficacy signal" from eti-cel in non-hodgkin's lymphoma, which the firm believes positions Cellectis well to be among the first companies to bring an allogenic CAR-T product for the treatment of hematological cancers to market.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for CLLS

Unlock Now

Valuation Metrics

The current forward P/E ratio for Cellectis SA (CLLS.O) is 0.00, compared to its 5-year average forward P/E of -1.45. For a more detailed relative valuation and DCF analysis to assess Cellectis SA's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-1.45

Current PE

0.00

Overvalued PE

0.20

Undervalued PE

-3.11

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

-2.72

Current EV/EBITDA

-2.20

Overvalued EV/EBITDA

-0.36

Undervalued EV/EBITDA

-5.08

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

5Y Average PS

4.59

Current PS

5.27

Overvalued PS

6.63

Undervalued PS

2.54

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

high growth stocks trading under $5

Intellectia · 184 candidates

Price: <= $5.00Annual Eps Yoy Growth: >= 20.0%Annual Revenue Yoy Growth: >= 20.0%

Ticker

Name

Market Cap$

TDH Holdings Inc

10.74M

ReTo Eco-Solutions Inc

2.60M

Iovance Biotherapeutics Inc

1000.00M

Loop Industries Inc

61.87M

Evaxion A/S

26.61M

Onconetix Inc

1.65M

Whales Holding CLLS

Long Focus Capital Management LLC

Bpifrance Participations SA

Trading Trends

People Also Watch

Frequently Asked Questions

What is Cellectis SA (CLLS) stock price today?

The current price of CLLS is 3.1 USD — it has increased 0.65

What is Cellectis SA (CLLS)'s business?

Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development, and commercialization of rational genome engineering technologies. The Company develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction, and biotherapeutics fields. Cellectis SA operates several subsidiaries. The Company operates in France and the United States, among others.

What is the price predicton of CLLS Stock?

Wall Street analysts forecast CLLS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CLLS is7.00 USD with a low forecast of 4.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Cellectis SA (CLLS)'s revenue for the last quarter?

Cellectis SA revenue for the last quarter amounts to NaN USD, decreased

What is Cellectis SA (CLLS)'s earnings per share (EPS) for the last quarter?

Cellectis SA. EPS for the last quarter amounts to USD, decreased

How many employees does Cellectis SA (CLLS). have?

Cellectis SA (CLLS) has 229 emplpoyees as of June 20 2026.

What is Cellectis SA (CLLS) market cap?

Today CLLS has the market capitalization of 309.88M USD.